Monash Women's, Monash Health, Clayton, Australia.
Department of Obstetrics & Gynaecology, Monash University, Clayton, Australia.
Hum Reprod. 2020 Nov 1;35(11):2408-2412. doi: 10.1093/humrep/deaa224.
Questions continue to be raised regarding the benefit of genetic assessment of embryos prior to transfer in IVF, specifically with regards to preimplantation genetic testing for aneuploidy (PGT-A). To evaluate and quantify these concerns, we appraised the most recent (2012-2019) randomized controlled trials on the topic. Only two of these six studies listed cumulative live birth rates per started cycle, with both eliciting a statistically non-significant result. This article describes the concern that a focus on results from the first embryo transfer compared to cumulative outcomes falsely construes PGT-A as having superior outcomes, whilst its true benefit is not confirmed, and it cannot actually improve the true pregnancy outcome of an embryo pool.
关于在体外受精 (IVF) 前对胚胎进行基因评估的益处,人们仍存在疑问,特别是针对胚胎植入前非整倍体检测 (PGT-A)。为了评估和量化这些担忧,我们评估了该主题的最新(2012-2019 年)随机对照试验。这六项研究中只有两项列出了每个启动周期的累积活产率,结果均无统计学意义。本文描述了一种担忧,即关注与累积结果相比的第一个胚胎移植的结果会错误地认为 PGT-A 具有更好的结果,而其真正的益处尚未得到证实,并且实际上不能改善胚胎库的真正妊娠结局。